ch 13 Flashcards

1
Q

Overview of the Liver

A

Largest gland in the body (~1400-1800 g)

Hepatocytes form ~80% mass, crucial to:
Detoxification of drugs and vits and hormones
metabolism of AA + ammonium
biochemical oxidative reaction

> 500 known functions (see Nelms Table 16.1)
“Secretory gland” (i.e. bile)

Huge functional reserve
~80-90% liver cells must be injured before
s/s of physiological dysfunction appear

Remarkable regenerative capacity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Blood Circulation To and From the Liver

A

Liver receives blood from:
Hepatic artery
Arterial blood that provides the livers o2 supply
Hepatic portal vein- venous blood drains from the digestive tract to the liver for nutrient processing/storage

Blood leaves the liver from:
Hepatic vein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Bile

A

Yellow/green fluid composed of:
Cholesterol, bile acids (salts), bilirubin, water, K, Na, bicarbonate, copper and other metals

Produced in the Liver__________

Stored in the gallbladder________

Emulsifying agent
Decreases surface tension and allows intestinal agitation to break up fat globules
Bile salts aid in absorption of fatty acids, monoglycerides, cholesterol, and other lipids by forming micelles that are soluble in chyme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Acute liver failure:

A

large proportion of hepatocytes are destroyed; often self-limiting (i.e. resolve in time with treatment, i.e. acute heptatis; obviously if get to certain state, may require liver transplant)

acute hepatitis, shock liver, acute liver failure
acute on chronic liver failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Chronic liver failure

A

defined by increased inflammation, infiltration of lymphocytes, plasma cells and hepatocyte apoptosis; will review each of the phases (fibrosis, cirrhosis etc in a couple slides)

fatty liver, steatosis
fibrosis
cirrhosis
hepatocellular carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Compensated liver disease:

Decompensated l

A

a person will not have symptoms related to their cirrhosis

iver disease: a person will present with symptomatic complications related to liver disease/cirrhosis (jaundice, ascites, HE, esophageal varices etc).
k

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

causes of liver disease

A

toxins: alcohol, meds

metabolic causes: obesity, wilsons disease

infection: viral hep a, s, c,e, bacterial - tuberculosis

immune mediated:autoimmune, primary biliary cirrhosis

other: carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Primary biliarycholangitis (PBC), also known asprimary biliary cirrhosis,

A

is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Primary sclerosing cholangitis(PSC)

A

) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. The underlying cause of the inflammation is believed to be autoimmunity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Amyloidosis

A

is a rare disease that occurs when a substance called amyloid builds up in your organs. Amyloid is an abnormal protein that is produced in your bone marrow and can be deposited in any tissue or organ.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Progression of Chronic Liver Disease

A

goes from normal liver to early cirrhosis to cirrhosis to wither a liver transplant or hepatocellular carcinoma

if the removal of the underlysing cause it taken away at early cirrohosis - the liver can go back to normal- if cirrhosis cannot iprove but can maintain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are the primary causes of liver disease

A

alcohol, obesity, viral hep

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Key Laboratory Parameters

A
“Liver function tests” / “liver panel”
Enzymes: ALP, ALT, AST, GGT, LDH
Proteins: Albumin, Total protein
Clotting studies: PTT, INR
Ammonia (present in blood in ionized form  NH4)
Bilirubin
Total (unconjugated)
Direct (conjugated)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Jaundice (Icterus)

A

Yellowish tint to body tissues
Eyes: Icteric sclerae

↑bilirubin
↑ RBC destruction
↓ bilirubin uptake / ↓ liver function
Bile duct obstruction

Pruritis
Itchy skin. ? Related to ↑bilirubin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Portal Hypertension

A

Elevated blood pressure in the hepatic vein
Blood flow forced backward, causing veins to enlarge
Primary symptoms/complications:
Ascites
Esophageal varices
Hepatic encephalopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ascites

A

alterations is systemic hemodynamics and build up of pressure causes fluid leaking into abdominal space.

(also why peripheral edema occurs, along with decreased albumin resulted in decreased oncotic pressure in blood vessels resulting in leaky vessels and fluid shifting in interstitial space)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How do they think ascites could impact nutrition/diet:

A

Full full quickly; anorexia, poor intake
Possible Fluid and Na restrictions (more on this later)

Physical observation  muscle wasting! Ribs, clavicle, arms
Use of PEG tubes in pt’s with ascites: mortality has been shown to be high and thus is not recommended.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Treatments:

of ascites

A

Paracentesis (protein also removed as part of fluid) – several litres can be removed at once (4L ascitic fluid has ~40-80g protein)

TIPS (transjugular intrahepatic portosystemic shunt) – surgical procedure where a shunt is placed such that blood flow is rerouted through the liver to the hepatic vein to decrease pressure.
DSRS (distal spenlorenal shunt) – splenic vein is disconnected from the portal vein and

19
Q

(Esophageal) Varices

A

Low-pressure veins in esophagus (and upper stomach) that become distended from increased pressure d/t portal HTN

20
Q

Use of Feeding Tubes in Patients with Chronic Liver Disease

A

Non-bleeding esophageal varices
Use of nasoenteric tubes (NG, NJ):
Risk low that placement of soft-tipped, fine-bore tube will precipitate variceal hemorrhage

Actively bleeding esophageal varices
Advise holding EN for 48-72h post-banding
Critically ill: Sengstaken-Blakemore Tube
No nasoenteric access
If suspected prolonged NPO, high malnutrition risk  PN

21
Q

Hepatic Encephalopathy (HE)

A

Syndrome of impaired mental status and abnormal neuromuscular function resulting from liver failure

S/S
Changes in mental status and personality
Mild confusion  Lethargy/disorientation  Somnolent but arousable  Coma
Neuromuscular changes

Contributing factors:
Degree of liver failure
Diversion of portal blood through venous systemic circulation
Bleeding from varices
Exogenous factors (i.e. sepsis)
22
Q

Pathogenesis of HE

A
Ammonia is key neurotoxin
Colon: major site of NH3 production
Healthy liver
NH4  urea, excreted by kidney
Diseased liver
NH4 bypasses liver metabolism and accumulates in systemic circulation
NH4 metabolized at extrahepatic sites (i.e. SM and brain) to glutamine
NH4 passes blood brain barrier
Accumulates in brain
23
Q

Plasma NH4 Levels

A

Often used in clinical setting as diagnostic tool for HE

BUT: Poor correlation b/w NH4 levels & HE

Plasma NH4 levels not required to make a diagnosis or helpful in monitoring effectiveness of NH4 lowering therapies

24
Q

Primary Treatments

A

Aimed at reducing circulating ammonia (NH3)

Lactulose
Non-absorbable disaccharide
Stimulates passage of NH3 from body tissues into gut lumen 
Inhibits intestinal NH3 production
Side effects?

Antibiotics
Decrease colonic concentration of bacteria that can produce NH3

25
Q

Malnutrition in Chronic Liver Disease

A

Highly prevalent
Non-alcoholic cirrhosis: 27-87%
Alcoholic cirrhosis: 34-82%

Correlates with severity of liver disease vs etiology

3 major causes of malnutrition in cirrhosis
factors resulting in low oral intake
physiological alterrations resulting in impaired digestion/ abosroption
impaired nutrition metabolism

26
Q

Cholestatis:

A

Decrease in bile flow due to impaired secretion by hepatocytes or to obstruction of bile flow through intra- or extrahepatic bile ducts

27
Q

caused of malnutrition in cirrhosis

Decreased oral intake

A

anorexia
N/V
EARLY SATIETY
DISCOMFORT

28
Q

caused of malnutrition in cirrhosis malabsorption and maldigestion

A

fat malabsorption
chronic pancreatitis
vit malabsoption
bacterail overgrowth

29
Q

caused of malnutrition in cirrhosis metabolic abnormalities

A

glucose intolerance
reducred glycogen stores

increased pro metabolism

increase lipd meta

30
Q

Skeletal Muscle Wasting / Sarcopenia in Cirrhosis

A

40-60% of patients with cirrhosis
Most severe sarcopenia seen in alcoholic cirrhosis
Supplemental nutrition does not improve clinical outcomes
Etiology: complex, multifactorial, poorly understood
Anabolic resistance
Accelerated lipolysis
Accelerated oxidation of aa’s
Increased autophagy-mediated proteolysis in muscle
Hyperammonemia  perturbations in muscle signaling pathways
? activate autophagy; ? activate myostatin

31
Q

Goals of Nutrition Therapy

A

Promote and maintain N balance
Promote liver regenration
prevent exacerbation of metabolic abnormalities
Treat Manutrition

32
Q

Strategies to Improve PO Intake in Liver Disease

A

nutrient dense foods
ONS
Small frequent meals
In hospital: EN may be warranted pending degree of malnutrition extent of disease

33
Q

Protein Considerations in HE

A

Long tradition of protein restriction (i.e. < 0.6 g/kg/d) in patients with HE
Rationale: ↑ protein consumption = ↑ NH3 production
Limited scientific basis (protein restriction not shown to improve mental state)

Considerations
Protein restriction: ↑ SM breakdown releases more N-containing AA that can contribute to further NH4 production
Severe protein restriction exacerbate malnutrition?

Protein recommendations: ~1.0-1.5 g/kg/d
Should not go below 0.8 g/kg/d

34
Q

Branched Chain Amino Acids (BCAA) & HE

A

Altered AA metabolism in liver failure can result in
↑ circulating levels of aromatic amino acids (AAA)
Phenylalanine, tyrosine, tryptophan
Corresponding ↓ plasma BCAA’s
Isoleucine, leucine, valine

Hypothesis: ↑ AAA can worsen HE as they cross the blood-brain barrier acting as false neurotransmitters
Therefore, could modification of ratio of BCAA:AAA attenuate HE?

35
Q

BCAA Supplementation & HE

A

Studies have not supported this hypothesis
BCAA supplementation can decrease AAA concentration but no improvement in HE

Other benefits of BCAA’s?
Anabolic

Specialized ONS- $$$$$

36
Q

Alcoholic Liver Disease (ALD)

A

Complex etiology/pathophysiology  Nelms Box 16.6 (p.452)

ALD spectrum of 3 disorders:
Fatty liver (steatosis)  hepatitis  cirrhosis
Heptotoxic alcohol threshold ALD likely to develop:
Males: 40 g (~4 drinks/d)
Females: 20 g (~2 drinks/d)
1 standard drink ~10 g alcohol
? kcal in 1 gram etoH:
37
Q

Thiamine

A

Chronic alcohol consumption can causethiamine deficiencyand thus reduced enzyme activity through several mechanisms, including inadequate dietary intake, malabsorption ofthiaminefrom the gastrointestinal tract, and impaired utilization ofthiaminein the cells

38
Q

Non-Alcoholic Fatty Liver Disease (NAFLD)

A

Hepatic manifestation of metabolic syndrome/insulin resistance

Accumulation of excess fat in liver cells (steatosis)
Non-alcohol related

May progress to NASH (non-alcoholic steatohepatitis)
Fat accumulation associated with liver cell inflammation & scarring

39
Q

difference b/w NAFLD and NASH

A

NAFLD refers to a spectrum of liver pathologies whereas NASH is one of the progressions on this spectrum
Steatosis – fatty liver
NASH is distinguished from steatosis by the presence of hepatocyte injury, inflammatory infiltration and/or fibrosis (result of collagen deposition)
PT = portal triad (hepatic artery, portal vein, bile duct)

40
Q

Risk Factors for the Development of NASH

A

adipose tissue inflammation
gut microbiota
oxidative stress hepatocyte apoptosis
inflmamation

41
Q

Role of Obesity and Lipotoxicity in the Development Chronic Metabolic Diseases (Including NAFLD)

A

he release of fatty acids from dysfunctional and insulin-resistant adipocytes re- sults in lipotoxicity, caused by the accumulation of trig- lyceride-derived toxic metabolites in ectopic tissues (liver, muscle, pancreatic beta cells) and subsequent ac- tivation of inflammatory pathways, cellular dysfunction, and lipoapoptosis. The cross talk between dysfunctional adipocytes and the liver involves multiple cell popula- tions, including macrophages and other immune cells, that in concert promote the development of lipotoxic liver disease, a term that more accurately describes the pathophysiology of nonalcoholic steatohepatitis

42
Q

he release of fatty acids from dysfunctional and insulin-resistant adipocytes re- sults in lipotoxicity, caused by the accumulation of trig- lyceride-derived toxic metabolites in ectopic tissues (liver, muscle, pancreatic beta cells) and subsequent ac- tivation of inflammatory pathways, cellular dysfunction, and lipoapoptosis. The cross talk between dysfunctional adipocytes and the liver involves multiple cell popula- tions, including macrophages and other immune cells, that in concert promote the development of lipotoxic liver disease, a term that more accurately describes the pathophysiology of nonalcoholic steatohepatitis

A

Diet and physical activity

10% weight loss (0.5-1.0 kg/wk)

Basic nutrition principles to promote weight loss

Areas of increased interest
Ketogenic diet
Bariatric surgery

Supplement with Vitamin E (800 IU/d)
PIVENS study (NEJM 2010; 362: 1675-1685)
Vitamin E supplementation resulted in histological improvement in NASH

43
Q

Complementary & Alternative Medicine (CAM)

A

Pt’s with liver disease have high CAM use
~30% (J Clin Gastroenterol, 2010; 44:240)

May interact with conventional treatments

ASPEN Core Curriculum handouts
Glutathione prodrugs, combined antioxidants, Vitamin E, S-adenosylmethionine, betain, Zinc, Silymarin, BCAA’s, Probiotics